Company or ticker...

Beam Therapeutics

Beam develops base-editing therapies that can rewrite single DNA letters.

Ticker

M. Cap

PS

PE

YTD

10MA

20MA

50MA

200MA

BEAM

2.8B

17.5

n/a

-2.74%

Key Facts

M. Cap

PS

PE

YTD

2.8B

17.5

n/a

-2.74%

10MA

20MA

50MA

200MA

$BEAM